Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate

NCT03257852 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT03257852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03257852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
September 29, 2017
Completion date
October 16, 2018
Enrollment
66 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis (ra)